Novo Nordisk’s Xultophy gains traction in antidiabetics market

Novo Nordisk, one of most renowned players in antidiabetics market has recently announced its findings that depicted how its novel drug – Xultophy, offered diabetes management benefits over other multiple daily injections of insulin (basal-bolus regimen).

Reportedly, the results of the DUAL VII clinical trial showed Xultophy to be a better option and a better antidiabetic drug to manage type II diabetes. Moreover, it was also revealed that more number of people preferred to stay on Novo Nordisk’s drug Xultophy than basal-bolus insulin therapy. Later, these patients reported that with Xultophy, they had a seemingly better experience in their diabetes management as well as in their mental health.

According to reports, Xultophy is an FDA approved injected combination drug consisting of insulin degludec and liraglutide (Victoza), a GLP-1 receptor agonist. This drug is a once-daily single pen injection offering both medications that are intended for adults diagnosed with type II diabetes and who are not able to manage glucose levels with less than 50 units of basal bolus insulin per day.

Industry analysts speculate Novo Nordisk’s commitment in discovering and developing new medicine like Xultophy, to majorly influence the global antidiabetics market trends. For the record, Novo Nordisk is headquartered in Denmark and is a global healthcare and medical devices company leading its way in diabetes care.

Experts further analyze that the commercialization of such drugs will enhance the options available for patients in antidiabetics care, which will ultimately lead to better outcomes for antidiabetics industry.

Commenting on Xultophy’s safety and effectiveness, Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, was quoted stating that this drug will not only help people with type II diabetes reach their blood glucose levels, but also help them to lose weight while reducing the risk of hypoglycaemia. He further said that Xultophy will be a key component in antidiabetics market that would make diabetes care much easier.